•
Apr 30, 2021

SAIC Q1 2022 Earnings Report

SAIC reported a strong start to fiscal year 2022 with increased revenues and earnings.

Key Takeaways

SAIC announced first quarter results for fiscal year 2022, with revenues increasing to $1.9 billion and diluted earnings per share increasing to $1.38. Net bookings were $4.2 billion, resulting in a book-to-bill ratio of 2.2 for the quarter. The company also increased the lower end of revenue and adjusted EBITDA margin and raised adjusted diluted EPS guidance for fiscal year 2022.

Revenues increased to $1.9 billion, reflecting approximately 7% total revenue growth.

Diluted earnings per share increased to $1.38; Adjusted diluted earnings per share increased to $1.94.

Net bookings of $4.2 billion; Book-to-bill ratio of 2.2 for the first quarter.

Company increased lower end of revenue and adjusted EBITDA margin and raised adjusted diluted EPS guidance for fiscal year 2022.

Total Revenue
$1.88B
Previous year: $1.76B
+6.9%
EPS
$1.94
Previous year: $1.38
+40.6%
Total Backlog
$24B
Previous year: $16.6B
+44.6%
Gross Profit
$217M
Previous year: $183M
+18.6%
Cash and Equivalents
$261M
Previous year: $276M
-5.4%
Free Cash Flow
$164M
Previous year: $358M
-54.2%
Total Assets
$5.81B
Previous year: $6.02B
-3.4%

SAIC

SAIC

Forward Guidance

SAIC updated its fiscal year 2022 guidance, assuming a negative COVID-19 impact of approximately $150 million in revenue and approximately $10 million in adjusted EBITDA. The guidance also assumes that support currently provided under Section 3610 of the CARES Act continues through the end of fiscal year 2022 (January 28, 2022) and excludes the announced acquisition of Halfaker and Associates, LLC.

Positive Outlook

  • Revenue: $7.15 billion - $7.30 billion
  • Adjusted EBITDA Margin: 8.7% to 8.8%
  • Adjusted Diluted EPS: $6.15 - $6.40
  • Free Cash Flow: $430 million to $470 million

Challenges Ahead

  • Assumes expected negative COVID-19 impact of approximately $150 million in revenue
  • Assumes expected negative COVID-19 impact of approximately $10 million in adjusted EBITDA.
  • Guidance assumes that support currently provided under Section 3610 of the CARES Act continues through the end of fiscal year 2022 (January 28, 2022)
  • Excludes the announced acquisition of Halfaker and Associates, LLC.